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Background: Bone morphogenic proteins (BMPs) promote the survival of neurons, suggesting a therapeutic
application of BMPs in the treatment of acute and chronic neurodegenerative disorders. However, the application
of recombinant BMPs in vivo is limited by their short half-life. To provide a continuous supply for functionally active
BMPs, we expressed BMP7, BMP2 and the BMP inhibitor Noggin under the control of rAAV vectors in vivo. For visual
control of rAAV-mediated BMP (v-BMP) expression we fused the secreted morphogenic polypeptides and the
fluorescent reporter protein Venus via the ‘ribosomal skip’ promoting 2A peptide-bridge.
Results: In primary cortical neurons, the rAAV-expressed morphogenic polypeptides were efficiently released from the
2A-Venus fusion precursors, were secreted, correctly processed and functionally active as shown by their effects on
Smad phosphorylation in HeLa cells and in primary neurons, by the protection of v-BMP7-transduced primary cortical
neurons against oxidative stress, and by the activation of BMP responsive GFP in v-BMP2 transduced reporter mice. In
the stroke model of middle cerebral artery occlusion rAAV-transduced v-BMP7 reduced the infarct size in mice.
Conclusion: Polycistronic rAAV vectors encoding secreted polypeptides and 2A-linked reporter proteins are potential
novel therapeutic tools for the treatment of neurological and neurodegenerative diseases. Using this technique we
documented that rAAV delivery of BMP7 reduced ischemic cell death in mice.
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Bone morphogenic proteins (BMP) are members of the
transforming growth factor-β (TGFβ) family. Mamma-
lians encode and express more than a dozen BMPs. Two
members, BMP2 and BMP7, are in clinical use for the
treatment of bone fractures providing evidence for the
therapeutic application of BMPs to regulate the viability
and differentiation of osteoblasts [1], which might be of
strong interest for other human cell types; in particular
for those in the nervous system. BMPs play an important
role during development of the nervous system [2]. In
adults, they stimulate adult neurogenesis, exert a neuro-
protective effect, and stimulate the regeneration of neu-
rons [3-5]. In models of ischemic stroke BMP7 reduced
the infarct size [4,6,7] and improved functional recovery* Correspondence: rolf.sprengel@mpimf-heidelberg.mpg.de
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reproduction in any medium, provided the orat delayed time points after stroke [3,4,7-9]. BMP7 also
exerted neuroprotective effects in models of Parkin-
son’s disease, spinal cord injury [10,11]. In addition,
BMP2 had neuroprotective properties in vitro [12,13]
and stimulated angiogenesis, neuronal differentiation,
and neurite outgrowth [14-16]. Although BMP2 is up-
regulated after cerebral ischemia [17], its function as
an endogenous neuroprotectant is controversial since
recombinant soluble Noggin, an antagonist of BMP2,
BMP4 and BMP7, demonstrates neuroprotective ef-
fects in models of stroke [18-20].
A major obstacle for the therapeutic use of BMPs is
the short half-life of the peptides; in the case of BMP7
about 30 min [21], precluding intravenous administra-
tion for chronic conditions. Transplanted cells secreting
BMPs or Noggin can be one option to solve this issue
[22,23] but viral gene therapy using lentiviruses or re-
combinant adeno-associated viruses (AAVs) might open
an attractive, well-defined alternative option for provi-
ding constant supply of recombinant BMP [24,25].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and Noggin in the brain of mice since rAAVs enable effi-
cient gene delivery in the CNS without inducing toxic or
inflammatory responses [26]. For visual inspection of
rAAV encoded gene transduction we expressed BMP2,
BMP7, and Noggin as fusion with a fluorescent protein
(FP) using the ribosomal skipping 2A peptide bridge from
Thosea asigna virus [27]. In contrast to conventional tech-
niques, such as the internal ribosomal entry site (IRES),
bidirectional and dual promoters, or co-infection of sev-
eral viruses, the ribosomal skipping leads to nearly equi-
molar ratios of the 2A-linked proteins [28-31].
In this study we demonstrate that BMP2, BMP7, or the
inhibitor Noggin can be functionally expressed by rAAV
encoded, 2A fused open reading frames together with
fluorescent reporter proteins. When released from the 2A
linked reporter proteins during protein translation, BMP2,
BMP7, and Noggin are secreted and are functionally ac-
tive. We found that rAAV-delivered BMP7 exerted neuro-
protective properties in vitro and in vivo suggesting that
this might represent a new approach for long-term admin-
istration of BMP7 in neurological diseases.
Results
Expression of secreted morphogenic proteins and
2A-linked Venus
To analyze whether BMP2, BMP7 and Noggin can be
functionally expressed in rAAV encoded gene transfer ex-
periments we generated several rAAV vectors by linking
the secretory proteins BMP7, BMP2 and Noggin via the
2A peptide to the cytosolic fluorescent protein Venus [32]
or to tdTomato (not shown) [33] in a single open reading
frame (Figure 1A).
For the functional analysis of the rAAV vectors in neu-
rons we first infected primary neurons by rAAVs encod-
ing the viral BMPs (v-BMP2 and v-BMP7) and viral
Noggin (v-Noggin) (Figure 1A). Seven days post infec-
tion (DPI 7) cell culture medium (supernatant, S) con-
tained a major amount of mature v-BMP7, v-BMP2, and
v-Noggin as revealed by immunoblots using an anti-2A
antibody selective for 18 amino acids of 2A-peptides that
remained at the C-terminus of v-BMP2, v-BMP7 and v-
Noggin after successful ribosomal skipping (Figure 1B).
For Noggin, three bands were visualized in immunoblots
of cell lysates corresponding to the unmodified protein
(26 kDa), the glycosylated protein (30 kDa), and the ma-
ture protein (32 kDa). In addition, in cell lysates the
anti-2A antibody detected the BMP7 and BMP2 precur-
sors, in the range of the predicted molecular weight
(MW) of 48 kDa and 45 kDa, respectively. The anti-2A
antibody also detected a Noggin-immunosignal at about
53 kDa, which might indicate residual Noggin-2A-Venus
fusion proteins that escaped the ribosomal skip. However,
the anti-GFP antibody revealed only minor amounts (about6%) of BMP7-2A-Venus and BMP2-2A-Venus full-length
proteins but no Noggin-2A-Venus fusion. This suggests
that the 53-kDa immunosignal for Noggin in the super-
natant represents Noggin dimers that can be detected
under low stringent reducing conditions during electro-
phoresis [34]. Thus, the ribosomal skipping and the secre-
tion of the target proteins encoded by the rAAVs were very
efficient. The minor amount of mature factors that can be
detected in the lysates of neurons is most likely due to the
crude, one-step separation procedure of supernatants and
lysates. In contrast to the almost complete secretion of
BMPs and Noggin, the secreted Venus (sVenus) which con-
tains the N-terminal signal sequence of Noggin (Figure 1C)
was only partially secreted and equal amounts of sVenus
were found in the supernatant and cell lysate using the
Venus cross reactive anti-GFP antibody (Figure 1D).
The immunocytology of rAAV-infected primary cortical
neurons on DPI 7 was in accordance with the concept that
2A-tagged v-BMP7, v-BMP2 and v-Noggin entered the
secretory pathway in rAAV transduced cells, since the 2A
immunoreactivity for all three factors showed nuclear ex-
clusion (Figure 1E). The immunofluorescence was associ-
ated with cell membranes, whereas the signal in v-Venus
transduced neurons was localized mainly in the cytosol in-
dicating that low expression of the virally transduced fac-
tors is not the reason for nuclear exclusion of their 2A
immunoreactivity. A similar change in the distribution of
the Venus fluorescence was found when the fluorescence
patterns of virally delivered sVenus and Venus (v-sVenus;
v-Venus) were compared (Figure 1E). Therefore, we
conclude that the subcellular immunosignal distribu-
tions of 2A-linked secreted and cytosolic proteins indi-
cate an efficient secretion of the secreted proteins in 2A
based polycistrons.
Efficient expression of 2A-linked secretory proteins in vivo
We aimed to use the rAAVs for the delivery of BMP2,
BMP7 and Noggin in the adult brain. Therefore, we ex-
amined the efficiency of the 2A-mediated co-expression
and ribosomal skipping of 2A-linked rAAV-encoded pro-
teins in the brain in vivo. We injected rAAV-BMP7-2A-
Venus, rAAV-BMP2-2A-Venus, rAAV-Noggin-2A-Venus,
rAAV-Venus and rAAV-sVenus into the cortex (CTX)
and hippocampus (HPC) of adult C57BL6/N mice. At DPI
14 we detected similar Venus fluorescence intensity spe-
cifically in rAAV injected brain regions for all rAAVs
(Figure 2A). The immune-histological staining with anti-
GFP and anti-2A antibodies showed cytosolic Venus
expression whereas v-BMP2, v-BMP7 and v-Noggin immu-
nosignals were nuclear excluded and were associated
with the cell membranes (Figure 2A, B). A similar cellu-
lar distribution could be observed for v-sVenus and v-
Venus in the HPC (Figure 2C). This strongly suggests that
the secretion of the rAAV expressed v-BMP7, v-BMP2
Figure 1 Coexpression and release of secretory proteins and Venus via the 2A peptide bridge in cultured neurons. A. Top, amino acid
residues of the 2A peptide from Thosea asigna virus (T2A). The ribosomal skipping site (lack of peptide bridge formation between G and P) is indicated
by a black arrowhead. Four amino acids (red) were added to create a constant C-terminal environment among different constructs. Bottom, schematic
diagram of rAAVs. The theoretical molecular weights for the expected proteins of the rAAV encoded polypeptides are indicated in kDa above
the boxed open reading frames. B. Primary cortical neurons (PCN) were infected with rAAVs expressing v-BMP7, v-BMP2 and v-Noggin. Immunoblots
revealed BMP2 and BMP7 precursors and mature secretory morphogenic proteins and some BMP7-2A-Venus and BMP2-2A-Venus full-length
proteins in lysates (L). In PCN supernatants (S) only mature morphogenic proteins could be detected. Venus was visible in PCN lysates and not
in the corresponding supernatants. Venus was detected by anti-GFP antibodies. Anti-beta-actin was used as loading control. C. Schematic drawing of
rAAVs encoding secreted Venus (sVenus) and cytosolic Venus. D. Immunoblots of PCN expressing rAAV-Venus (v-Venus) and rAAV-sVenus (v-sVenus).
The v-Venus was not present in PCN supernatants, whereas sVenus was observed in lysates and supernatants using anti-GFP antibodies. E. After
infecting PCNs with the indicated rAAV constructs immunocytology using anti-2A and anti-GFP antibodies showed co-expression of cytosolic
Venus (green) and nuclear excluded BMPs or Noggin (red). On the right the expression of v-sVenus and v-Venus is depicted. Cell nuclei are
stained with DAPI (blue) indicating the high efficiency of rAAV infection. Scale bar, 20 μm.
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tions. The cellular resolution of v-BMP2, v-BMP7 and
v-Noggin in the stratum radiatum revealed that glia as
well as neurons express the rAAV delivered morpho-
genic factors (Figure 2A). Since the ubiquitous CAG
promoter controls the expression of the rAAV delivered
2A-linked morphogenic factors the astroglial expression
was expected.In crude hippocampal extracts mature v-BMP2, v-
BMP7 and v-Noggin could be detected together with
their v-BMP2 and v-BMP7 precursors and Noggin dimer
of v-Nogin (Figure 2C). As already noticed in virally trans-
duced primary neurons (Figure 1B), the electrophoretic
mobility of the v-BMP2 precursor (at 49 kDa) is slower
than expected (45 kDa). Since this slower mobility of the
v-BMP2 45-kDa precursor was consistently observed in
Figure 2 Efficient co-expression of secretory BMPs, Noggin, and Venus in the cortex and the hippocampus of rAAV injected mice at
DPI 14. A. Confocal fluorescent immune histological images of sections from rAAV infected adult mouse brains (hippocampus and cortex)
demonstrated cytosolic expression of Venus (green) and v-BMPs or v-Noggin (red) visualized by anti-GFP and anti-2A antibodies, respectively. The
insets in the middle row show the expression of v-BMPs or v-Noggin in glia and neurons in the stratum radiatum (St.r) at high magnifications. In
the insets of the bottom row, overlay of the CA2 region in the hippocampus is depicted demonstrating the nuclear exclusion of the 2A-tagged
peptide factors (yellow) in cells expressing Venus (green) in the nucleus and the soma. A. Scale bar, 500 μm. Scale bar inserts, 15 μm. B. Fluorescent
immune-histological images show the nuclear excluded 2A-tagged v-BMP7 and v-BMP2 in rAAV infected neurons of cortical layer V/VI. Scale bar,
20 μm. C. Confocal fluorescent immune-histological images of sections from rAAV infected adult mouse brains show expression of v-Venus and
membrane associated v-sVenus in the hippocampus and cortex. Lower panel: High magnifications of the hippocampal CA1 region of the somatic and
nuclear excluded Venus immunoreactivity. Scale bar, 500 μm. Scale bar insets, 15 μm. D. After rAAV infection immunoblots detected precursors and
mature protein factors in hippocampal extracts. Precursors (Prec.), dimerized Noggin (dNoggin) and mature proteins are indicated by arrowheads.
Beta-actin was used as loading control.
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property of the v-BMP2 precursor in our electrophoretic
system.
2A-released secretory proteins are biologically active
To analyze whether 2A-tagged v-BMP2, v-BMP7 and
v-Noggin expressed in brain cells are bioactive we ana-
lyzed v-BMP2, v-BMP7 and v-Noggin induced Smad1/5/8
phosphorylation, the neuroprotection afforded by v-BMP7
against H2O2 toxicity and the v-BMP2 activation of the
BMP2 BRE:GFP reporter gene in the BMP reporter mouse
brains [35].
First, we collected at different time point cell culture su-
pernatants from PCN that express v-BMP2, v-BMP7,
and v-Noggin and compared their immunoreactivity tocommercially available morphogenic proteins. Thus, anti-
BMP7 detected r- and v-BMP7 and anti-Noggin r- and v-
Noggin in immunoblots (Insets, Figure 3A, B) whereas the
anti-BMP2 could only be used in ELISA for v-BMP2 de-
tection (histogram, Figure 3B) demonstrating immune-
cross-reactivity of homologous recombinant and virally
expressed morphogenic proteins. Most of r-BMP7 and
r-Noggin were found in the fully reduced form with the
expected molecular weights of 13.5 and 26 kDa, re-
spectively. The cystines containing forms of BMP2 and
Noggin exhibit reduced SDS-PAGE electrophoretic
mobility and are the dominant isoforms for v-BMP2
and v-Noggin (Insets, Figure 3A, B). Substantial
amounts of v-BMP2, v-BMP7 and v-Noggin B could be
detected in PCN culture media when compared to the
Figure 3 2A-released v-BMPs and v-Noggin are biologically active. A. BMP7 in lysates (L) and culture medium (S) of rAAV infected PCNs at
different time points. Inset: Anti-BMP7 immunoblots of L (4 μl) and S (12 μl) used for quantification. B. Time course of v-BMP2 expression in PCN
determined by ELISA of 4 μl L and 12 μl S. Inset: Noggin immunoblot of L and S of rAAV-Noggin-2A-Venus infected PCN at DPI 6. Precursor and
released peptides are indicated by arrowheads; cystines containing forms by open arrows. C. Anti pSmad immunoblots of PCN (top) and HeLa
cells (bottom) treated for 4 h with recombinant proteins or conditioned medium from rAAV infected PCNs as indicated. Ctrl.: non-infected PCN.
Loading control: β-actin. D. left: H2O2 induced death of PCN as shown by lactate dehydrogenase (LDH) release 24 h after adding H2O2. Values are
means ± SEM, One-way ANOVA, p < 0.0001. *p < 0.05, ***p < 0.0001 in comparison to untreated groups. D, E. Pretreatment with r-BMP7 (1.25 nM)
and rAAV-mediated v-BMP7 expression reduced H2O2 induced LDH release in PCN. R-BMP7 was added 30 min before H2O2. One-way ANOVA,
p < 0.0006. *p < 0.05 (Tukey’s posthoc test). LDH is given relative to controls (Ctrl.). F, V-BMP2 specific induction of the BMP responder GFP
in BRE:GFP mice. RGB overlay fluorescent images of hippocampal DG region in coronal brain sections of (left) BRE:GFP mice injected with
rAAV-BMP2-2A-tdTomato and (right) with PBS as control. GFP was visualized by anti-GFP (green), and cells nuclei with DAPI (blue). tdTomato
auto-fluorescence is in red. Hilus region (hi); molecular layer (ml) of the dentate gyrus (DG); mossy fiber projections (mf). Arrows indicate GFP expressing
cells in the granular cell layer (gr). Blood vessels show an unspecific fluorescence in both brain sections (stars). Scale bar; 0.5 mm.
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blot (Insets, Figure 3A, B).
We treated PCN with conditioned supernatants of
PCN cultures (Figure 3A, B) since it was documented
that BMP2 and BMP7 stimulate the phosphorylation of
Smad1/5/8 (pSmad1/5/8) whereas Noggin inhibits theformation of pSmad [36]. As controls we applied recom-
binant r-BMP7, r-BMP2, r-Noggin (100 ng/ml) and super-
natant from non-transfected PCN. The Smad1/5/8
specific immunoblots showed that r-BMPs and v-BMPs
increased the level of pSmad 4 h after stimulation whereas
supernatants from v-Noggin or v-Venus expressing cells
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(Figure 3C; upper panel). The identical treatment of HeLa
cells provided a similar result (Figure 3C; lower panel). In
HeLa cells the v- and r-BMP7 stimulation induced higher
pSmad1/5/8 levels than v- and r-BMP2. The v- and r-
Noggin treated HeLa cells showed lower pSmad1/5/8
levels than HeLa cells stimulated with conditioned super-
natants harvested from Venus expressing or uninfected
PCN (Figure 3C; lower panel). Thus, the efficient stimula-
tion of pSmad1/5/8 by v-BMP2 and v-BMP7 strongly sug-
gested that the 2A-tagged v-BMP2 and v-BMP7 are
secreted as bioactive proteins from rAAV infected PCN.
Since our goal was the application of the virally delivered
BMPs for neuroprotection and since reactive oxygen species
are known to be involved in the pathophysiology of several
brain disorders, including stroke, we exposed primary cor-
tical neurons to H2O2 investigating the protective activity of
rAAV-delivered BMP7. On day in vitro (DIV) 11 we treated
PCN with H2O2 and 24 h later we measured the cell toxicity
indicator lactate dehydrogenase (LDH) in the supernatant of
PCN cultures. As shown in Figure 3D H2O2 exposure
induced neuronal toxicity in a H2O2 concentration-
dependent manner. For the subsequent experiments we
used 0.2 mM H2O2 that induced about 30 % of the glo-
bal toxicity obtained by 1 M H2O2 exposure. Treatment
with r-BMP7 itself (1.2 nM to 12.5 nM) did not affect
LDH release (Figure 3D, right panel). However, treat-
ment of DIV 11 neurons with r-BMP7 (1.2 nM) 30 min
before H2O2 exposure significantly reduced H2O2-in-
duced LDH levels in the medium (Figure 3E). Interest-
ingly, infection of PCN with rAAV-BMP7-2A-Venus at
DIV 4 also protected PCN from H2O2-induced exposure
at DIV 11 (Figure 3E). These results indicate that, given
shortly before the noxious stimulus or chronically ad-
ministered by rAAV delivery several days before H2O2
treatment, v-BMP7 has protective properties in primary
neurons.
To provide additional evidence for the bioactive ex-
pression of v-BMPs in the adult brain we injected
rAAV-BMP2-2A-tdTomato into the hippocampus and
cortex of BRE:GFP reporter mice [35]. Two weeks after
rAAV delivery we detected the majority of GFP po-
sitive cells in the granular cell layer of the dentate
gyrus (DG) in addition to some sparse GFP immuno-
positive neurons and glia in the cortex at the injection
site (Figure 3F). The presence of the GFP immunoposi-
tive cells could not be observed in PBS-infected BRE:
GFP mice (Figure 3F) suggesting that the virally deliv-
ered v-BMP2 is functionally active. The poor GFP ex-
pression by rAAV transduced v-BMP2 might reflect
the low sensitivity of the BRE:GFP reporter in brain tis-
sue, since injection of r-BMP2 did lead to GFP positive
cells 24 or 48 h after injection of rBMP2 (not shown).
Thus, in summary, our results collectively show thatBMP2, BMP7 and can be expressed and secreted as na-
tive peptides in neuronal cultures and in adult brains
as rAAV encoded 2A fusions.
Virally expressed BMP7 has a neuroprotective effect
in MCAO
To study the neuroprotective effects of v-BMP2 and v-
BMP7 in adult mice we aimed to analyze whether v-
BMP2 and v-BMP7 can decrease the infarct size after
occlusion of the middle cerebral artery (MCAO) in
adult mice. Since the stereotactic delivery of rAAV in
adult mice is restricted to the injection site of the
virus (about 1 mm3) we injected rAAV into the lateral
ventricle and the hippocampi of newborn (P0) mice
for robust virally mediated gene expression [37].
Injected mice did not show behavioral abnormalities
during adolescence and adulthood. In sagittal, im-
munhistological brain sections of P0 injected mice ro-
bust and widespread expression of nuclear excluded,
membrane-attached v-BMP2 and v-BMP7 could be vi-
sualized 8 weeks after rAAV injection with strongest
expression in neurons of the cortex and the hippo-
campus (Figure 4A). In contrast to adult rAAV
injected mice (Figure 2A) the expression of the rAAV-
encoded 2A-linked morphogenic factors was restricted
to neurons with very few rAAV expressing astroglia
(Figure 4A insets).
In a second cohort of eight-week-old mice injected at
P0 with rAAV-BMP7-2A-Venus, rAAV-BMP2-2A-Venus,
rAAV-Noggin-2A-Venus and rAAV-Venus MCAO was
performed. In this model of ischemic strokes, infarcts are
mainly limited to the cortex. When cortical infarct vol-
umes were quantified 48 h after MCAO, rAAV-mediated
overexpression of v-BMP7 (Figure 4B, (i)v-BMP7), signifi-
cantly reduced infarct volumes, whereas the rAAV medi-
ated expression of v-Venus, v-BMP2 and v-Noggin did
not alter infarct volumes (Figure 4B). In another inde-
pendent experimental group, we confirmed the protect-
ive effect of v-BMP7 in MCAO (Figure 4B, (ii)v-BMP7)
and showed in these mice that v-BMP7 did not affect
the cerebral blood flow (Figure 4C). To further investi-
gate the protective properties of v-BMP7 in vivo, we
analyzed neuronal apoptosis after MCAO in eight-
week-old P0 rAAV-BMP7-2A-Venus injected animals.
Apoptosis was evaluated in the periphery of the ische-
mic area by TUNEL staining on coronal sections at the
level of the anterior commissure. We detected signifi-
cantly fewer TUNEL-positive cells in mice expressing
v-BMP7 compared to rAAV-Venus infected or naïve
mice (Figure 4D).
Our results indicate that rAAV-induced neuronal over-
expression of BMP7 is protective in MCAO and that
rAAV-mediated polycistronic gene transfer can be ap-
plied to study cerebral ischemia in vivo.
Figure 4 rAAV-transduced v-BMP7 decreases ischemic brain damage. A. Efficient, long-lasting v-BMP2 and v-BMP7 expression eight weeks
after rAAV injection into the brains of neonatal mice. Fluorescent immunohistological images of sagittal brain sections are in gray scale. CTX,
cortex; HPC, hippocampus; OB, olfactory bulb; LV, epithelium of lateral ventricles. Scale bar, 1 mm. Insets: confocal images of cortical neurons
expressing v-BMP2 and v-BMP7. Cellular resolutions show neurons expressing v-BMP2 and v-BMP7 and one v-BMP2 positive astrocyte. Scale bar,
30 μm. B. Top: silver-stained coronal brain sections with marked, unstained infarcts 48 h after MCAO. Bottom: quantification of infarct volumes.
The brain edema did not differ between groups. Values are means ± SEM. First experiment (i): v-Venus, n = 8; v-BMP7, n = 9; v-BMP2, n = 12;
v-Noggin, n = 7); one-way ANOVA, P = 0.0049, *, p < 0.05 (Tukey’s posthoc test). Second experiment (ii): Ctrl., n = 4; v-Venus, n = 8; v-BMP7,
n = 8; one-way ANOVA, P = 0.0265, *, p < 0.05 (Tukey’s posthoc test). C. Virally delivered v-BMP7 had no influence on cerebral blood flow measured
by Doppler sonography before and after MCAO in (ii). Values were normalized to Ctrl. before MCAO; means ± SEM. D. The rAAV-expressed v-BMP7
reduced apoptosis after MCAO. Top: apoptotic nuclei were quantified 48 h after MCAO on TUNEL-stained coronal sections in indicated areas. Middle:
images of TUNEL- and DAPI-stained (total number of nuclei) brain sections after MCAO in gray-scale. Scale bar, 50 μm. Bottom: quantification of apoptotic
nuclei after MCAO was determined in relation to the total number of DAPI stained nuclei in all three indicated areas. Values are means ± SEM (n = 3).
One-way ANOVA, P = 0.0002, *, p < 0.05 (Tukey’s posthoc test).
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The morphogenic protein BMP7 has neuroprotective
properties in vitro. However, in vivo administration is lim-
ited by the short half-life and the large amounts of bio-
logically active BMP7 that need to be administered (at
least 10 mg/kg body weight) [8], which might explain why
recombinant BMP7 reduced the infarct volume in some,
but not all experimental stroke studies [4,7-9]. Using
rAAV expressed BMP7 we observed a 2-fold reduction in
the infarct size, suggesting that rAAV vectors represent a
superior mode for the delivery of biological active BMP7.
Previous work has revealed an anti-apoptotic effect of
BMP7 in neurons in vitro [38,39]. Our work extends this
finding, demonstrating that BMP7 reduces apoptotic cell
death in vivo as rAAV expression of BMP7 significantly
decreased the number of TUNEL-positive cells in the per-
iphery of the ischemia.
In contrast to a previous study [18], the viral expres-
sion of Noggin, an extracellular inhibitor of BMP2,
BMP4 and BMP7, had no effect on the infarct size al-
though we verified that the rAAV expressed Noggin
was bioactive by decreasing the level of Smad phos-
phorpylation of HeLa cells. Besides the different time
points for the analysis after MCAO (2 days in this
study versus 14 days in [18]) a lower expression level
of biological active Noggin in our system cannot be ex-
cluded. Similarly, low expression levels of v-BMP2
might be responsible for the lack of neuroprotection in
our MCAO experiments.
Our study was not designed to analyze long-term ef-
fects of BMP2, BMP7 and Noggin, but rather was
designed to propose a convenient, reliable route for pro-
longed delivery of short-lived peptide hormones. Future
work will be required to explore the potential of BMPs
and BMP inhibitors in regenerative treatment of stroke
and other neurodegenerative diseases. Similarly, a para-
crine or autocrine neuroprotective activity of the v-
BMP7 needs to be investigated in future studies, using
neuron specific rAAV vectors.
Our study illustrates that 2A-tagged BMP2, BMP7
and Noggin can be co-expressed in 2A-linked fusions
with a reporter protein in neurons using rAAVs as gene
transfer vectors. In cells of adult mouse brains the 2A
induced ribosomal skip [29] was very efficient and no
full-length 2A-fusion protein composed of the secretory
polypeptides, the 2A peptide linker and Venus could be
detected in adult mouse brains. After or during transla-
tion the N-terminal secretory protein precursors and
the C-terminal reporter protein were differentially
sorted as separated proteins into the cytosol or func-
tionally assembled in secretory pathways indicating that
the C-terminally attached 2A peptide did not inhibit the
BMP2, BMP7 and Noggin bioactivity and that v-BMP7
is similar active as r-BMP7 in vitro [40].Conclusion
Polycistronic expression of 2A-linked peptide hormones
and a reporter gene using rAAVs provide a convenient
and promising gene therapeutic tool for the genetic de-
livery of neuroprotective factors.
Methods
Animal experimentation
Molecular, biochemical experiments and genetic manip-
ulations of mice were licensed by the regional council in
Karlsruhe, Germany, under project licenses 35–9185.81/
G171-10. Animal experiments and were performed ac-
cording to the animal welfare guidelines of the Max
Planck Society. Efforts were made to minimize numbers
of animals used.
Cloning strategies of specific rAAV vectors
The plasmid pAAV-CAG-Noggin-2A-Venus was gener-
ated by PCR-isolating the CMV enhancer chicken β-actin
(CAG) promoter from plasmid pAAV-CMV-Rluc2A-
Venus, GenbankID: KC152484 [41], with KpnI and EcoRI
restriction sites and subcloning it between XbaI and EcoRI
in pAAV-Syn-Noggin-2A-Venus [27] by 5′ blunt and
EcoRI ligation to replace the synapsin promoter. The hu-
man BMP2 and human BMP7 genes were amplified by
PCR from the pcDNA3.1-BMP2 and pcDNA5-BMP7
template DNA using specific primers to replace Noggin in
pAAV-CAG-Noggin-2A-Venus using EcoRI and XhoI re-
striction sites to construct pAAV-CAG-BMP2-2A-Venus
and pAAV-CAG-BMP7-2A-Venus. The plasmids pAAV-
CAG-BMP7-2A-Tomato, pAAV-CAG-BMP2-2A-Tomato
and pAAV-CAG-Noggin-2A-Tomato were generated by
replacing Venus by tdTomato from pAAV-Syn-iCre-2A-
Tomato using BamHI and BsrGI restriction sites. To
generate pAAV-CAG-Venus, Noggin-2A was deleted in
pAAV-CAG-Noggin-2A-Venus by EcoRI and BamHI re-
striction digest and subsequent religation of the vector.
Generation of rAAV vectors
Recombinant AAV gene transfer vectors were generated
by molecular cloning of specific gene cassettes into
rAAV2-based expression vectors [42], containing viral
cis-acting elements required for genome replication and
packaging, a woodchuck posttranscriptional regulatory
element (WPRE), a bovine growth hormone polyadeny-
lation site (bGHpA), two flanking inverted terminal re-
peats (ITRs) of serotype 2 (S2) and the cytomegalovirus
enhanced chicken beta-actin promoter (CAG) for effi-
cient expression in cells of the brain. All constructs were
confirmed by sequencing.
Preparation and delivery of rAAV vectors
Recombinant AAVs of serotype 1 and 2 were generated
as described [27] and purified by AVB Sepharose affinity
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was determined by real-time PCR using primers and a
probe against WPRE: WPRE forward primer: 5′-
TGCCCGCTGCTGGAC-3′; WPRE reverse primer: 5′-
CCGACAACACCACGGAATTG-3′; and WPRE probe:
5′-CAGTGCCCAACAGCC-3′ (1.0–6.0 × 1012 viral ge-
nomes (vg)/ml, TaqMan Assay, Applied Biosystems). In
addition, the filling rate of the rAAV preparation was de-
termined by electron microscopy. Purified virus samples
were applied to carbon-coated electron microscopy grids,
negatively stained with 1% uranyl acetate and rinsed with
ultrapure water. Representative images of selected areas
were taken using transmission electron microscopy at
6,3000x magnification (Zeiss 912 Omega Transmission
Electron Microscope). The filling rate was determined by
manually counting filled and empty particles using ImageJ
(NIH). Empty capsids were distinguished from filled cap-
sids, resulting from the uptake of uranyl acetate in the
capsid core or from collapse staining of the particle. The
genomic titers (genome copies (gc)/ml) and the filling rate
(%) were as follows: rAAV-BMP7-2A-Venus, 1.69 × 1012,
88%; rAAV-BMP2-2A-Venus, 1.86 × 1012, 92%; rAAV-
Noggin-2A-VENUS, 1.02 × 1012, 49%; rAAV-Venus, 2.90 ×
1012, 64%; and for rAAV-sVenus, 5.96 × 1012, 98%. The
infectivity was determined in primary neurons. Primary
cortical neurons were infected with rAAVs on DIV 4
at multiplicities of infection (MOI) of 2 × 103 gc/cell. The
expression of rAAV-transduced proteins in rat primary
neurons was evaluated on DPI 7 by Venus fluorescence,
immunoblots, immunoassay, or immunostainings [27,44].
BMP stimulation of HeLa cells
HeLa cells were incubated at 37°C and 5% CO2 in a hu-
midified atmosphere. For stimulation experiments HeLa
cells were plated in 12-well plates in MEM containing
5% FCS (Invitrogen) at a density of 1.5 × 105 in 1 ml/
well. The following day medium was changed to serum-
free MEM. On the third day medium was replaced by
1 ml conditioned medium taken from infected primary
cortical neurons or 1 ml DMEM containing 100 ng/μl
recombinant proteins (r-BMP7, r-BMP2 and r-Noggin,
R&D Systems) to stimulate HeLa cells.
Primary cortical neuron culture
Cultures of primary cortical neurons were prepared from
cerebral cortices of E16 NMRI mice as described previ-
ously [45]. Briefly, cortices were dissected in ice-cold
PBS supplemented with Hepes (7.38 g/l) and glucose
(6 g/l). Pooled cortical tissues were dissociated by incu-
bation with trypsin-EDTA for 8 min at 37°C, followed by
mechanical trituration using a fire-polished Pasteur pip-
ette. After resuspension in Neurobasal (NB) medium con-
taining 1 × B27, 0.5 mM L-glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin, 2 × 105 cells per well wereplated in 24-well plates precoated with poly-D-lysine
(50 μg/ml). On DIV 1 half of the medium was exchanged
by fresh NB medium containing 5% fetal bovine serum.
Then, on DIV 4 and DIV 8 half of the medium was ex-
changed with fresh NB until DIV 10–12 when cells were
used for experiments. On DIV 11 half of the medium was
exchanged with fresh medium containing r-BMP7 (R&D
Systems). Thirty minutes later, H2O2 was added to the
medium for 24 hours. Culture media were collected to
measure levels of lactate dehydrogenase (LDH) using the
cytotoxicity detection kit (Roche). Here, six wells were an-
alyzed per condition and the assays were performed in du-
plicate. Per well, 75 μl of supernatant was added to 75 μl
of assay reagent and incubated for 30 min at room
temperature. LDH activity was determined by colorimetry
according to the LDH assay kit’s instructions and
expressed as percentage of LDH activity of untreated cells
(LDH %Control).
Constitutive release of v- BMP7, v-BMP2 and v-Noggin in
PCN
Primary cortical neurons (PCN) were cultured as de-
scribed above. On DIV 4 PCN were infected with rAAV-
BMP7-2A-Venus, rAAV-BMP2-2A-Venus or rAAV-
Noggin-2A-Venus at a MOI of 1 × 103 gc/cell. Lysates
(L, 4 μl) and supernatants (S, 12 μl) were collected and
analyzed in immunoblots or by ELISA.
Characterization of rAAV in immunoblots
Infected primary cortical neurons were harvested with
RIPA lysis buffer (50 mM Tris–HCl, pH 7.6; 150 mM
NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS)
containing protease inhibitor cocktail (Complete, Roche)
7 days after rAAV infection. Brain tissue (cortex and
hippocampus) was collected 8 weeks after virus injection
and homogenized in 25 mM Hepes buffer containing a
protease inhibitor cocktail on ice. Proteins were separated
by SDS-PAGE (10% separating and 4% stacking gels) and
transferred onto nitrocellulose membranes. Immunoblots
were probed with monoclonal mouse anti-GFP (1:8000,
Clontech), polyclonal rabbit anti-2A (1:2000, Millipore),
polyclonal rabbit anti-phospho-Smad1/5/8 (1:1000, Cell
Signaling Technology), polyclonal rabbit anti-BMP7
(1:1000, Abcam), and monoclonal mouse anti-β-actin
(1:5000) antibodies. Horseradish peroxidase-linked anti-
rabbit or anti-mouse was used as secondary antibodies
(1:15,000, Vector Laboratories), and blots were visua-
lized by enhanced chemiluminescence (ECL kit, GE
Healthcare). Immunoblots were quantified using ImageJ
(NIH).
Characterization of rAAV expression by immunostaining
Cultured primary cortical neurons on DPI 7 or brains
from virus-injected mice on DPI 56 were fixed with 4%
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obtained from brains. Immunostaining was performed with
polyclonal rabbit anti-2A (1:1000) or polyclonal chicken
anti-GFP (1:5000, Abcam) and Cy3-coupled anti-rabbit or
FITC-coupled anti-chicken secondary antibodies (1:400,
Jackson ImmunoResearch).
Stereotaxic rAAV delivery into brains of adult mice
Stereotaxic rAAV injection into adult C57BL6/N mice
was performed according to a protocol described pre-
viously [46]. The following coordinates relative to bregma
were used for injection: anteroposterior −2 mm; mediolat-
eral ±1.5 mm; dorsoventral from pial surface −1.55 mm
for DG, −1.05 mm for CA1, −0.35 for CTX. In brief, ani-
mals were anesthetized with an intraperitoneal injection
of a mixture of ketamine hydrochloride (Inresa Arzneimit-
tel; 100 mg per kilogram body weight) and xylazine
(Inresa Arzneimittel; 10 mg per kilogram body weight) in
PBS. After loss of reflexes the animal was fixed in a small
animal stereotaxic frame (David Kopf instruments) and
eyes were covered with bepanthene. The skull was ex-
posed and levels were adjusted using the Kopf digital dis-
play console (David Kopf instruments). Coordinates were
set and a small craniotomy was made at the defined pos-
ition into the skull using an OS-40 drilling device (Osada
Electronic). Virus solution was sucked into a glass micro-
pipette with an inner diameter of 9 μm by applying back-
pressure and a total volume of 264 nl was injected into
the three different injection sites at a rate of 50 nl/min.
After injection, the micropipette was kept in place for 5
min to avoid backflow of the injected virus during micro-
pipette retraction. The scalp was sutured, and the animal
was placed on a heating pad until recovery from surgery
and then returned to its home cage.
BRE: GFP mice
Adult BRE: GFP reporter mice [35] were analyzed on DPI
10 after rAAV or PBS injection in the cortex and hippo-
campus. Coronal sections were immunostained as de-
scribed above using mouse anti-GFP (1:1000, Clontech)
and Cy3-anti-mouse (Jackson Immunoresearch) for en-
hanced GFP detection. The Cy3 fluorescence was con-
verted to the green channel in the RGB color mode in
Photoshop.
Stereotaxic rAAV delivery into brains of newborn mice
Stereotaxic rAAV injection into neonate C57BL6/N mice
at P0 was performed as described previously [37]. The
following coordinates relative to lambda were used for
injection: Lateral ventricle (LV), rostral 1 mm, lateral
1 mm and ventral 1.5 mm; HPC, rostral 2 mm, lateral
0.7 mm and ventral 1.5 mm. Briefly, newborn pubs were
separated from their mother and cryoanesthetized for
5 min. Purified rAAV1/2 were infused into LV and HPC(1 μl virus per injection site) of neonates according to
the defined coordinates at 200 nl/sec through a 33-
gauge beveled needle via microprocessor-controlled WPI
(World Precision Instruments) infusion-pump driving a
100 μl syringe. After injection, the hand-held needle was
kept in place for additional 3 s to avoid backflow of the
injected virus. Following injection the pups were col-
lected on a 37°C warm plate for recovery. After regai-
ning normal body color and full mobility, the injected
pups were rolled in home cage bedding and returned to
their mother as a group. Injected animals were kept until
experiments were performed.
Middle cerebral artery occlusion (MCAO)
Eight-week-old male C57BL/6 N mice that had been in-
fected with rAAV vectors on P0 were anesthetized by in-
traperitoneally injecting 15 μl of 2.5% avertin per g body
weight. Middle cerebral artery occlusion (MCAO) was
performed as described previously [47,48]. A skin incision
was made between the ear and the orbit on the left side
and the temporal muscle was removed by electrical coagu-
lation. Then, the MCA was exposed and occluded by
microbipolar coagulation. Rectal temperature was main-
tained at 37°C during surgery by a heating pad and moni-
tored continuously. After 48 hours of MCAO, mice were
deeply anesthetized with avertin and perfused transcar-
dially with Ringer’s solution. Brains were removed and im-
mediately frozen on dry ice. Serial coronal cryosections
(20 μm in thickness) were cut every 400 μm and stained
with a silver technique [48]. Stained sections were scanned
at 300 d.p.i., and the infarct area was measured using Ima-
geJ (NIH). To correct for edema formation, the difference
between areas of the left and right hemispheres was sub-
tracted from the measured silver-negative area [49]. For
calculating the infarct volume, the infarct areas were
added and multiplied by the distance between the sections
(400 μm). Based on previous MCAO experiments in our
laboratory we calculated that, in experiments with four
groups, 12 mice per group were required to detect a 40%
change of infarct size with a power of >0.8 and a p < 0.05
by one-way ANOVA. Experimenters were blinded for the
treatment group.
TUNEL staining and quantification
For quantification of apoptosis after MCAO, terminal
deoxynucleotidyl transferase- mediated dUTP-biotin nick
end labeling (TUNEL) was performed on cryosections
using the in-situ-cell death detection kit (Roche). Sections
were air-dried for 10 min at RT and postfixed in 4% PFA
for 30 min. Then, sections were washed twice in PBS for
5 min and subsequently permeabilized in 0.1% sodium
citrate, 0.1% TrtionX-100 in PBS. Sections were washed
twice in PBS for 5 min and incubated with TUNEL reac-
tion mix (50 μl per section, TUNEL-enzyme: labeling
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After washing in PBS and DAPI-staining for 5 min at
RT sections were washed in PBS and mounted with
Mowiol/DABCO (Merck/Sigma-Aldrich). For combined
TUNEL and fluorescence immunostaining, immuno-
histochemistry was performed as described above. To
quantify the percentage of apoptotic cells fluorescence
images were acquired at 10x magnification in three op-
tical fields of the penumbra and analyzed using ImageJ
(NIH). The number of DAPI and TUNEL positive cells
was counted manually. Experimenters were blinded for
the treatment group.
ELISA assays
Culture supernatants or lysates of infected PCN were col-
lected and BMP2-immunoassay was performed in a 96-
well plate according the manufacturer’s instructions (R&D
systems). The optical density of each well was measured at
450 nm using the VersaMax microplate reader (Molecular
Devices). Protein concentrations were determined accord-
ing to appropriate BMP2 standard curves.
Statistical analysis
Data were analyzed using GraphPad Prism 5 (Graphpad)
and results are presented as mean ± standard error of
the mean (SEM) of the indicated number of independent
replicates unless otherwise indicated. Two-tailed Stu-
dent’s t test was used for comparisons between two inde-
pendent groups. For comparing more than two groups
one way analysis of variance (ANOVA) was performed
followed by Turkey’s multiple comparison post hoc test.
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